CTIS2024-513901-30-00
Recruiting
Phase 1
ong-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector - LTF-307
Bluebird Bio Inc.0 sites88 target enrollmentMay 14, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bluebird Bio Inc.
- Enrollment
- 88
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/ legal guardian(s), Treated with drug product for therapy of SCD in a bluebird bio\-sponsored clinical study
Exclusion Criteria
- •There are no exclusion criteria for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector2024-513901-30-00Bluebird Bio Inc.3
Not yet recruiting
Phase 4
A study that helps in Observing patients suffering from Sickle Cell Disease, when given a treatment of crizanlizumab in Middle Eastcountries and India (SPOTLIGHT)CTRI/2022/06/043467ovartis Healthcare Pvt Ltd
Enrolling By Invitation
Not Applicable
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene TherapySickle Cell DiseaseNCT04628585bluebird bio85
Terminated
Not Applicable
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and IndiaSickle Cell DiseaseNCT05020873Novartis Pharmaceuticals44
Recruiting
Not Applicable
Sickle Cell Outcome ResearchNL-OMON29491A1,000